Literature DB >> 10917898

Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits.

J Yamakoshi1, M K Piskula, T Izumi, K Tobe, M Saito, S Kataoka, A Obata, M Kikuchi.   

Abstract

The antiatherogenic effect of soy protein with intact isoflavones is well established, but the effects of isoflavones without soy protein have not been determined. We investigated the antiatherogenic effect of an isoflavone aglycone-rich extract (containing 429.4 mg/g isoflavone aglycones) without soy protein from fermented soy in cholesterol-fed rabbits. We fed 12-wk-old New Zealand white male rabbits diets containing 1 g/100 g cholesterol with 0, 0.33 or 1 g/100 g isoflavone aglycones for 8 wk. We also fed the rabbits a diet containing 1 g/100 g cholesterol with 1.09 g/100 g soy saponin-rich extract, a component other than isoflavone aglycones in the isoflavone aglycone-rich extract. Controls did not consume cholesterol, isoflavone aglycones or saponins. The isoflavone aglycone- and saponin-rich extracts did not affect the serum lipid profile of cholesterol-fed rabbits. The serum concentration of daidzein in its conjugated form was significantly higher in the high isoflavone group than in the low isoflavone group. The level of cholesteryl ester hydroperoxide (ChE-OOH) induced by CuSO(4) in plasma in the high isoflavone group was significantly less than that in the cholesterol group, and the ChE-OOH levels of LDL in the low and high isoflavone groups were significantly less than those in the cholesterol group. The ChE-OOH levels in plasma and LDL in the saponin group did not differ from the cholesterol group. In the aortic arch, the cholesterol concentration was significantly lower in the high isoflavone group, and malondialdehyde concentration was significantly lower in the low and high isoflavone groups compared with the cholesterol group; however these concentrations in the saponin group did not differ from those in the cholesterol group. The atherosclerotic lesion area of the aortic arch was significantly lower in the isoflavone groups (26.3% lower in the low isoflavone group and 36.9% lower in the high isoflavone group) than in the cholesterol group. The lesion areas were not different in the soy saponin and cholesterol groups. Immunohistochemical analysis revealed fewer oxidized LDL-positive macrophage-derived foam cells in atherosclerotic lesions in the aortic arch of isoflavone groups compared with that of the cholesterol group. These results suggest that the antioxidative action of isoflavones and their antioxidative metabolites inhibit the oxidation of LDL, thereby exerting an antiatherosclerotic effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10917898     DOI: 10.1093/jn/130.8.1887

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  25 in total

1.  Effects of Tomato and Soy Germ on Lipid Bioaccumulation and Atherosclerosis in ApoE-/- Mice.

Authors:  Brendon W Smith; Rita J Miller; Kenneth R Wilund; William D O'Brien; John W Erdman
Journal:  J Food Sci       Date:  2015-07-14       Impact factor: 3.167

2.  Soy isoflavones reduce heat shock proteins in experimental atherosclerosis.

Authors:  I Rosier Olimpio Pereira; D Saes Parra Abdalla
Journal:  Eur J Nutr       Date:  2005-11-24       Impact factor: 5.614

3.  Female Mice Exhibit Abdominal Aortic Aneurysm Protection in an Established Rupture Model.

Authors:  Anna Z Fashandi; Michael Spinosa; Morgan Salmon; Gang Su; William Montgomery; Alexis Mast; Guanyi Lu; Robert B Hawkins; J Michael Cullen; Ashish K Sharma; Gorav Ailawadi; Gilbert R Upchurch
Journal:  J Surg Res       Date:  2019-11-04       Impact factor: 2.192

4.  Soy protein containing isoflavones favorably influences macrophage lipoprotein metabolism but not the development of atherosclerosis in CETP transgenic mice.

Authors:  Leiko Asakura; Patrícia M Cazita; Lila M Harada; Valéria S Nunes; Jairo A Berti; Alessandro G Salerno; Daniel F J Ketelhuth; Magnus Gidlund; Helena C F Oliveira; Eder C R Quintão
Journal:  Lipids       Date:  2006-07       Impact factor: 1.880

5.  Aqueous extract of Piper sarmentosum decreases atherosclerotic lesions in high cholesterolemic experimental rabbits.

Authors:  Adel A Amran; Zaiton Zakaria; Faizah Othman; Srijit Das; Santhana Raj; Nor-Anita M M Nordin
Journal:  Lipids Health Dis       Date:  2010-04-30       Impact factor: 3.876

6.  Can stevioside in combination with a soy-based dietary supplement be a new useful treatment of type 2 diabetes? An in vivo study in the diabetic goto-kakizaki rat.

Authors:  Per B Jeppesen; Stig E Dyrskog; Andreas Agger; Soren Gregersen; Michele Colombo; Jianzhong Xiao; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2007-02-10

7.  Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study.

Authors:  Daniela C U Cavallini; Raquel Bedani; Laura Q Bomdespacho; Regina C Vendramini; Elizeu A Rossi
Journal:  Lipids Health Dis       Date:  2009-01-07       Impact factor: 3.876

8.  Genistein supplementation inhibits atherosclerosis with stabilization of the lesions in hypercholesterolemic rabbits.

Authors:  Choong-Sik Lee; Su-Jin Kwon; Sun-Young Na; Seung-Pyung Lim; Jung-Hee Lee
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

9.  Effects of isoflavone-supplemented soy yogurt on lipid parameters and atherosclerosis development in hypercholesterolemic rabbits: a randomized double-blind study.

Authors:  Daniela C U Cavallini; Dulcinéia S P Abdalla; Regina C Vendramini; Raquel Bedani; Laura Q Bomdespacho; Nadiége D Pauly-Silveira; Graciela F de Valdez; Elizeu A Rossi
Journal:  Lipids Health Dis       Date:  2009-10-08       Impact factor: 3.876

10.  Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study.

Authors:  Chen-Yu Liu; Yi-Hsiang Hsu; Ming-Tsang Wu; Pi-Chen Pan; Chi-Kung Ho; Li Su; Xin Xu; Yi Li; David C Christiani
Journal:  BMC Cancer       Date:  2009-01-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.